A Deep Dive into Chronic Plaque Psoriasis Market 2025: Key Drivers, Growth Factors, and Projections 2025-2034

What Are the Market Size and Growth Forecast for the Chronic Plaque Psoriasis Market?
In the past few years, there has been a significant growth in the market size of chronic plaque psoriasis. It is expected to grow from $20.79 billion in 2024 to $22.32 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The increase during the historical period can be attributed to several factors, including a rise in psoriasis cases, higher occurrences of co-morbidities, improved reimbursement policies, an upsurge in the consumption of alcohol and smoking, and the advent of telemedicine.

The market for chronic plaque psoriasis is projected to experience robust expansion in the upcoming years. The anticipated market value will hit $29.33 billion in 2029, with a compound annual growth rate (CAGR) of 7.1%. Numerous factors contributing to this surge during the forecast period encompass the fluctuating global prevalence of cpp, rising instances of autoimmune diseases, increased allocations in healthcare budgets, an aging population, and a growing demand for effective treatment methods. The forecast period will also witness significant trends such as the development of biologic treatments, the introduction of oral small molecule inhibitors, the integration of digital health, personal medicine, and the arrival of biosimilars.

What Is Contributing to the Growth of the Chronic Plaque Psoriasis Market?
The rise in instances of immune system malfunctioning is foreseen to accelerate the expansion of the chronic plaque psoriasis market. Immune system malfunctioning is a condition where the immune mechanism fails to work efficiently, resulting in a heightened vulnerability to infections, autoimmune illnesses, and cancer. Growth in immune system malfunction cases can be linked to elements like genetic preconditions, environmental catalysts, malnutrition, chronic stress, and a growing incidence of autoimmune diseases and infections, including HIV. Managing immune system malfunction is crucial in treating chronic plaque psoriasis, as the immune system erroneously sets off an excessive generation of skin cells, leading to inflammation and plaque formation. For example, in December 2022, the National Psoriasis Foundation, a nonprofit entity based in the US, reported that psoriasis affects over 8 million Americans. On a global scale, the disease affects 125 million individuals, representing 2 to 3% of the total population. Consequently, the escalating instances of immune system malfunctioning are propelling the growth of the chronic plaque psoriasis market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20726&type=smp

Which Key Market Leaders Are Driving Chronic Plaque Psoriasis Industry Growth?
Major companies operating in the chronic plaque psoriasis market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Biogen Inc., UCB S.A., Dr. Reddy's Laboratories, Innovent Biologics Inc., Dong-A ST Co. Ltd., Alumis GmbH Co KG, Zai Lab Limited, GC Cell Corporation, Affibody AB, Nimbus Therapeutics, Bio-Thera Solutions, Can-Fite Biopharma, Celgene Corporation, Kadmon Pharmaceuticals, Aldeyra Therapeutics Inc., Arcutis Biotherapeutics

What Are the Major Trends Shaping the Chronic Plaque Psoriasis Market?
Leading organizations in the chronic plaque psoriasis market are concentrating their efforts on creating cutting-edge therapies such as IL-17A and IL-17F inhibitors, to enhance the treatment solutions for chronic plaque psoriasis. These inhibitors represent targeted biological treatments meant to inhibit interleukin-17A and interleukin-17F - two pro-inflammatory cytokines crucial to the immune response, and thus, help manage inflammation in illnesses like chronic plaque psoriasis. For instance, in October 2023, biopharmaceutical firm UCB S.A., based in Belgium, disclosed that the U.S. FDA approved BIMZELX (bimekizumab-bkzx) for adult patients with critical to severe plaque psoriasis who qualify for systemic therapy or phototherapy. Bimekizumab stands as the pioneer medication approved for psoriasis that specifically targets and inhibits interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two crucial cytokines implicated in inflammatory responses. This approval was backed by data from three large-scale Phase 3 trials, namely BE READY, BE VIVID, and BE SURE, which collectively evaluated its safety and efficacy in 1,480 patients suffering from moderate to severe plaque psoriasis.

What Are the Main Segments in the Chronic Plaque Psoriasis Market?
The chronic plaque psoriasis market covered in this report is segmented -

1) By Drug Class: Biologics, Small Molecule Drugs
2) By Route Of Administration: Injectable, Oral, Topical
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

Subsegments:
1) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors (IL-12, IL-23, IL-17, IL-22), T-Cell Inhibitors, Others
2) By Small Molecule Drugs: Phosphodiesterase 4 (PDE4) Inhibitors, Janus Kinase (JAK) Inhibitors, Retinoids, Others

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/chronic-plaque-psoriasis-global-market-report

Which Geographic Area Leads the Chronic Plaque Psoriasis Market?
North America was the largest region in the chronic plaque psoriasis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic plaque psoriasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Is Covered In The Chronic Plaque Psoriasis Global Market Report?

- Market Size Analysis: Analyze the chronic plaque psoriasis Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the chronic plaque psoriasis Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the market.
- Market Contribution: Evaluate contributions of different segments to the overall chronic plaque psoriasis market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the chronic plaque psoriasis market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20726

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.